Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, China; Institute of Immunology, University of Science and Technology of China, China.
Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, China.
Immunol Lett. 2020 Jul;223:33-43. doi: 10.1016/j.imlet.2020.04.009. Epub 2020 Apr 23.
Hepatocellular carcinoma (HCC) is a world-wide health problem. Poor and delayed diagnoses as well as high recurrence rate resulting in high mortality rate. In this study, we established a patient-derived xenograft (PDX) model from HCC patient, and continuously maintained with subcutaneous passage more than 20 times. This HCC PDX tumor exhibited the same histological characteristics with the HCC patient and could be used to verify therapeutic effect of liver cancer. We further evaluated this PDX model by experimental chemotherapy, demonstrating that this HCC PDX model was sensitive to sorafenib treatment. Further, the potential of natural killer cell-based immunotherapy for HCC was tested using this model. We found that NK92 cells effectively suppressed the tumor growth in vivo and prolonged the survival time of HCC-bearing PDX mice. This study indicates that HCC PDX model is a good platform to testify the efficacy of preclinical chemotherapy and immunotherapy.
肝细胞癌 (HCC) 是一个全球性的健康问题。诊断不准确和延迟以及高复发率导致高死亡率。在这项研究中，我们从 HCC 患者中建立了一个患者来源的异种移植 (PDX) 模型，并通过皮下传代连续维持超过 20 次。这个 HCC PDX 肿瘤与 HCC 患者具有相同的组织学特征，可用于验证肝癌的治疗效果。我们进一步通过实验化疗评估了这个 PDX 模型，表明这个 HCC PDX 模型对索拉非尼治疗敏感。此外，我们还使用这个模型测试了基于自然杀伤细胞的免疫疗法的潜力。我们发现 NK92 细胞有效地抑制了体内肿瘤的生长，并延长了 HCC 荷瘤 PDX 小鼠的生存时间。这项研究表明，HCC PDX 模型是一个很好的平台，可以验证临床前化疗和免疫疗法的疗效。
